Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 Trials
Por:
Thaçi, D, Puig, L, Motegi, SI, Papp, K, Gold, LS, Kircik, L, Sofen, H, Fernández-Peñas, P, Herranz, P, Vestergaard, C, Huang, YH, Dossenbach, M, Elmaraghy, H, Gallo, G, Rueda, MJ, Casillas, M, Yang, C, Agel, H, Falqués, M, Nosbaum, A
Publicada:
1 ene 2026
Resumen:
The ADvocate trials (NCT04146363, NCT04178967) investigated adults/adolescents with moderate-to-severe atopic dermatitis (AD) receiving lebrikizumab (LEB) monotherapy, using percent improvement in the Eczema Area and Severity Index (EASI). In clinical trials, percent EASI improvement is used to compare study arms and measure treatment effect size/impact. In clinical practice, however, absolute EASI scores are used (especially in Europe), as they measure an individual's disease state regardless of baseline severity. This post-hoc analysis assessed absolute EASI response-EASI <= 7, <= 5, <= 3 and <= 1-from the ADvocate trials to understand LEB efficacy in adults/adolescents with moderate-to-severe AD. Week-16 data from patients receiving LEB 250 mg Q2W (n=564) were compared with placebo (n=287). Across baseline moderate/ severe/very severe EASI and baseline Investigator's Global Assessment (IGA) 3/4, significantly higher percentages of patients receiving LEB than those receiving placebo achieved each absolute EASI response. Week-16 LEB EASI 75 responders (n=284) and per-protocol LEB non-responders (n=215) were assessed through week 52. Absolute EASI scores were generally low and stable among responders and reduced among non-responders. Overall, LEB was associated with high rates of durable absolute EASI response, even in cases of high baseline severity or suboptimal week-16 outcomes. Results reflect clinically meaningful improvements that could help guide clinical practice.
Filiaciones:
Thaçi, D:
Univ Lubeck, Inst & Comprehens Ctr Inflammatory Med, Lubeck, Germany
Puig, L:
Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Dermatol, Barcelona, Spain
Motegi, SI:
Gunma Univ, Grad Sch Med, Dept Dermatol, Maebashi, Japan
Papp, K:
Alliance Clin Res & Prob Med Res, Waterloo, ON, Canada
Univ Toronto, Temerty Fac Med, Div Dermatol, Toronto, ON, Canada
Gold, LS:
Henry Ford Hlth Syst, Detroit, MI USA
Kircik, L:
Icahn Sch Med Mt Sinai, Dermatol, New York, NY USA
Indiana Univ Sch Med, Dermatol, Indianapolis, IN USA
Phys Skin Care PLLC, Louisville, KY USA
DermRes PLLC, Louisville, KY USA
Skin Sci PLLC, Louisville, KY USA
Sofen, H:
Univ Lubeck, Inst & Comprehens Ctr Inflammatory Med, Lubeck, Germany
Univ Calif Los Angeles, Los Angeles, CA USA
Fernández-Peñas, P:
Univ Lubeck, Inst & Comprehens Ctr Inflammatory Med, Lubeck, Germany
Univ Sydney, Westmead Hosp, Sydney Med Sch, Dept Dermatol, Sydney, NSW, Australia
Herranz, P:
Univ Lubeck, Inst & Comprehens Ctr Inflammatory Med, Lubeck, Germany
Hosp Univ La Paz, Dept Dermatol, Madrid, Spain
Vestergaard, C:
Univ Lubeck, Inst & Comprehens Ctr Inflammatory Med, Lubeck, Germany
Gunma Univ, Grad Sch Med, Dept Dermatol, Maebashi, Japan
Aarhus Univ Hosp, Dept Dermatol & Venereol, Aarhus, Denmark
Huang, YH:
Chang Gung Univ, Chang Gung Mem Hosp, Linkou Branch, Dept Dermatol, Taoyuan 333, Taiwan
Chang Gung Univ, Sch Med, Taoyuan 333, Taiwan
Dossenbach, M:
Eli Lilly & Co, Indianapolis, IN USA
Elmaraghy, H:
Eli Lilly & Co, Indianapolis, IN USA
Gallo, G:
Eli Lilly & Co, Indianapolis, IN USA
Rueda, MJ:
Eli Lilly & Co, Indianapolis, IN USA
Casillas, M:
Eli Lilly & Co, Indianapolis, IN USA
Yang, C:
Eli Lilly & Co, Indianapolis, IN USA
Agel, H:
Almirall SA, Barcelona, Spain
Falqués, M:
Almirall SA, Barcelona, Spain
Nosbaum, A:
Hosp Civils Lyon, South Lyon Hosp, Allergol & Clin Immunol Dept, Pierre Benite, France
Green Submitted, gold
|